| Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors Y Ergun, SA Esen, M Bardakci, G Ucar, Z Kalkan, Z Urakci, E Seyran, ... Cancer Biomarkers 34 (2), 329-336, 2022 | 4 | 2022 |
| Evaluation of clinical and prognostic factors for primary gastric diffuse large B-cell lymphoma: Single-center experience M Bardakci, DD Esmer, E Hafizoglu, K Karaman, OF Kuzu, H Karakas, ... Journal of Cancer Research and Therapeutics, 2023 | 2 | 2023 |
| Retrospective Analysis of Demographic and Laboratory Data of Patients with Hepatocellular Carcinoma: Single Center Experience M Bardakçı, Y Ergün, K Yalçın Acta Oncologica Turcica 52 (1), 64-72, 2019 | 2 | 2019 |
| Clinical features and prognostic factors in thymoma and thymic carcinoma D Bayram, S Sekmek, M Kayaalp, M Bardakçı, E Hafızoğlu, G Uçar, ... Indian Journal of Thoracic and Cardiovascular Surgery, 1-9, 2024 | 1 | 2024 |
| Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet … S Kahraman, M Bardakci, MB Aykan, S Yasar, C Erol, M Hizal, MB Akinci, ... Journal of cancer research and therapeutics 19 (2), 347-354, 2023 | 1 | 2023 |
| Does Prognostic Nutritional Index Predict Survival in Operated Papilla Vateri Tumors? A Single-centre Experience M Bardakci, E Hafizoglu, F Tugba Kos, D Uncu Methodology, 2020 | 1 | 2020 |
| Are the clinical trials in lung cancer an advantage for patients in developing countries? C Erol, M Hizal, S Kahraman, M Bardakci, D Sener Dede, MB Akinci, ... Journal of Clinical Oncology 42 (16_suppl), e20523-e20523, 2024 | | 2024 |
| Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment M Bardakci, H Karakas, D Bayram, N Avci, S Kitapli, M Ozen, F Aslan, ... Scientific Reports 14 (1), 10632, 2024 | | 2024 |
| Anaplastik Lenfoma Kinaz Mutant Küçük Hücreli Dışı Akciğer Kanserinde Güncel Tedaviler M BARDAKÇI, B BİLGİN Turkiye Klinikleri Medical Oncology-Special Topics 17 (2), 45-51, 2024 | | 2024 |
| Immune Efficacy of Immunotherapeutic Agents for Hepatocellular Carcinoma M BARDAKÇI, MAN ŞENDUR Turkiye Klinikleri Medical Oncology-Special Topics 17 (1), 82-86, 2024 | | 2024 |
| Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III … M Bardakci, D Demirtas Esmer, E Hafizoglu, S Yaslikaya, TB Genc, ... Oncology 101 (11), 723-729, 2023 | | 2023 |
| Major and minor salivary gland cancers: A multicenter retrospective study MB Hacioglu, B Erdogan, M Bardakcı, E Algın, B Gulbagcı, I Hacibekiroglu, ... Head & Neck 45 (7), 1643-1653, 2023 | | 2023 |
| JOURNAL of ONCOLOGICAL SCIENCES Y ERGÜN, G UÇAR, SA ESEN, M BARDAKÇI, Z KALKAN, Z URAKÇI, ... Journal of Oncological Sciences 9 (3), 176-80, 2023 | | 2023 |
| Management and prognosis of patients with cancer of unknown primary: 20 years of experience M Bardakci, E Algin, B DÜGEROĞLU, Ö Bal, FT KÖŞ, D UNCU Turkish Journal of Medical Sciences 53 (6), 1722-1731, 2023 | | 2023 |
| Association of Inflammatory Markers with Treatment Response in Immune Checkpoint Inhibitors M BARDAKÇI, Ö BALa, FT KÖŞ, DD ESMER, E HAFIZOĞLU, ... Journal of Oncological Sciences 9 (3), 158-65, 2023 | | 2023 |
| Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience C Erol, M Bardakçi, M Hizal, S Kahraman, E Yekedüz, D Güven, M Aykan, ... Journal of Oncological Science 9 (2), 2023 | | 2023 |
| Primer Apendiks Malignitelerinin Klinik Prezantasyonu ve Prognostik Faktörler: Retrospektif bir değerlendirme M BARDAKÇI, DD ESMER, E HAFIZOĞLU, H KARAKAŞ, Ö BAL, E ALGIN, ... Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 7 (2), 296-304, 2023 | | 2023 |
| Efficacy of postoperative radiotherapy (PORT) in stage IIIA-N2 non-small cell lung cancer: Meta-analysis of randomized controlled studies Y Ergun, G Ucar, Y Acikgoz, M Dirikoc, SA Esen, M Bardakci, C Karacin, ... ANNALS OF ONCOLOGY 33, S88-S88, 2022 | | 2022 |
| 120P Efficacy of postoperative radiotherapy (PORT) in stage IIIA-N2 non-small cell lung cancer: Meta-analysis of randomized controlled studies Y Ergün, G Uçar, Y Açıkgöz, M Dirikoç, SA Esen, M Bardakçı, C Karaçin, ... Annals of Oncology 33, S88, 2022 | | 2022 |
| İmmün Kontrol Noktası İnhibitörlerinin Kas-İskelet Sistemi ve Nadir Görülen Toksisitelerinin Yönetimi M BARDAKÇI, Ö BAL Turkiye Klinikleri Medical Oncology-Special Topics 15 (1), 61-66, 2022 | | 2022 |
